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Abstract: Purpose: We assessed the predictive potential of positron emission tomography (PET)/CT-
based radiomics, lesion volume, and routine blood markers for early differentiation of pseudoprogression
from true progression at 3 months. Experimental Design: 112 patients with metastatic melanoma treated
with immune checkpoint inhibition were included in our study. Median follow-up duration was 22 months.
716 metastases were segmented individually on CT and 2[18F]fluoro-2-deoxy-D-glucose (FDG)-PET imag-
ing at three timepoints: baseline (TP0), 3 months (TP1), and 6 months (TP2). Response was defined
on a lesion-individual level (RECIST 1.1) and retrospectively correlated with FDG-PET/CT radiomic
features and the blood markers LDH/S100. Seven multivariate prediction model classes were generated.
Results: Two-year (median) overall survival, progression-free survival, and immune progression–free sur-
vival were 69% (not reached), 24% (6 months), and 42% (16 months), respectively. At 3 months, 106
(16%) lesions had progressed, of which 30 (5%) were identified as pseudoprogression at 6 months. Patients
with pseudoprogressive lesions and without true progressive lesions had a similar outcome to responding
patients and a significantly better 2-year overall survival of 100% (30 months), compared with 15% (10
months) in patients with true progressions/without pseudoprogression (P = 0.002). Patients with mixed
progressive/pseudoprogressive lesions were in between at 53% (25 months). The blood prediction model
(LDH+S100) achieved an AUC = 0.71. Higher LDH/S100 values indicated a low chance of pseudopro-
gression. Volume-based models: AUC = 0.72 (TP1) and AUC = 0.80 (delta-volume between TP0/TP1).
Radiomics models (including/excluding volume-related features): AUC = 0.79/0.78. Combined blood-
/volume model: AUC = 0.79. Combined blood/radiomics model (including volume-related features):
AUC = 0.78. The combined blood/radiomics model (excluding volume-related features) performed best:
AUC = 0.82. Conclusions: Noninvasive PET/CT-based radiomics, especially in combination with blood
parameters, are promising biomarkers for early differentiation of pseudoprogression, potentially avoiding
added toxicity or delayed treatment switch.
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Pipeline step Parameter Range of values 
Removal of correlated features Pearson’s r Unif(0,1) 
Feature selection with false 
discovery rate 
The highest uncorrected p-value 
for features to keep 
Unif(alpha_min*, 1) 
Feature selection with logistic 
regression model regularized with 
elastic net 
The maximum number of selected 
features 
Unif{1, max_features**} 
Inverse of regularization strength 2Unif(-4,10) 
Elastic-net mixing parameter Unif(0,1) 
Classification with logistic regression 
regularized with L2 penalty 
Inverse of regularization strength 2Unif(-5,10) 
* a minimal significance level that retains max_features,  
** a predefined maximal number of features that can be selected. 
Table S1. Tuning parameters. 
 
Outcome All patients Patients with progressive lesions at TP1 















Total (N, %) 112 (100%) 9 (8%) 16 (14%) 11 (10%) 
Median OS (months) NR* (30 - NR) 30 (27 - NR) 10 (7 - 18) 25 (11 - NR) 
Median PFS (months) 6 (3 - 10) NR (12 - NR)  5** 7 (7 - 16) 
Median iPFS (months) 16 (8 - 33) NR (12 - NR) 7 (5 - 33) 7 (7 - 16) 
2-year OS (%) 69% (58% - 77%)  100%**  15% (3% - 38%)  53% (21% - 77%)  
2-year PFS (%) 24% (16% - 33%) 67% (5% - 95%)  0%**  0%**  
2-year iPFS (%) 42% (32% - 51%) 80% (20% - 97%) 25% (1% - 67%)  0%**  
*NR - not reached 
** 95% confidence intervals could not be estimated 
Table S2. Summary of patient outcome of the individual groups (with landmark analysis) The landmark 
method was applied, that is all events before 5 months were excluded. 95% confidence intervals were provided 
in parentheses. PP-only patients were the best performing group, with a similar outcome compared to responding 
patients. TPD-only patients presented a significantly worse OS of 10 vs. 30 months in the PP-only group 
(p=0.002, FWER=0.010). Patients with mixed PP&TPD were in between both other groups. 
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Outcome All patients Patients with progressive lesions at TP1 















Total (N, %) 112 (100%) 9 (8%) 16 (14%) 11 (10%) 
Median OS (months) NR* (30 - NR) 30 (27 - NR) 9 (7 - 18) 25 (11 - NR) 
Median PFS (months) 6 (3 - 10) 2 (1 - NR) 2** 2 (2 - 4) 
Median iPFS (months) 16 (8 - 33) NR (1 - NR) 2 (2 - 4) 2 (2 - 4) 
2-year OS (%) 69% (58% - 77%)  100%**  14% (2% - 36%)  53% (21% - 77%)  
2-year PFS (%) 24% (16% - 33%) 30% (5% - 61%)  0%**  0%**  
2-year iPFS (%) 42% (32% - 51%) 53% (18% - 80%) 6% (0% - 25%)  0%**  
*NR - not reached 
** 95% confidence intervals could not be estimated 
Table S3. Summary of patient outcome of the individual groups (without landmark analysis) 95% 
confidence intervals were provided in parentheses. PP-only patients were the best performing group, with a 
similar outcome compared to responding patients. TPD-only patients presented a significantly worse OS of 9 vs. 
30 months in the PP-only group (p=0.001, FWER=0.007). Patients with mixed PP&TPD were in between both 
other groups.   
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Fig. S1 Feature weights of the multivariate models for PP-prediction 
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Fig. S3 Distribution of pseudoprogression and true progression and association with OS, PFS and iPFS 
(no landmark). 
 
